ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 962

Profiling at the Single-Cell Level Reveals Evidence for Antigen-Driven Oligoclonal Expansion of Citrullinated Vimentin-Specific CD4+ T Cells in Peripheral Blood of Rheumatoid Arthritis (RA) Patients

Soi Cheng Law1, Hendrik Nel1, Jamie Rossjohn2,3, Hugh H Reid3, Nicole L La Gruta4 and Ranjeny Thomas1, 1The University of Queensland Diamantina Institute, Translational Research Institute, Princess Alexandra Hospital, Brisbane, Australia, 2Institute of Infection and Immunity, Cardiff University, School of Medicine, Heath Park, Cardiff, England, 3Department of Biochemistry and Molecular Biology, School of Biomedical Sciences, Monash University, Clayton, Melbourne, Australia, 4Department of Microbiology & Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, Australia

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: citrullinated vimentin and rheumatoid arthritis (RA), T cells

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 8, 2015

Title: Rheumatoid Arthritis - Human Etiology and Pathogenesis I

Session Type: ACR Concurrent Abstract Session

Session Time: 2:30PM-4:00PM

Background/Purpose:

RA is associated with shared epitope (SE)+ HLA-DRB1 alleles, including HLA-DRB1*0401, and development of anti-citrullinated protein autoantibodies. The preferential binding of citrullinated vimentin to HLA-DRB1*0401 and the correlation between disease activity and the frequency of citrullinated vimentin-specific T cells suggest that citrullinated vimentin selects and expands antigen-experienced T cells in SE+ RA patients. TCR diversity is generated through gene rearrangement, insertions and deletions of the genes encoding the Vα and Vβ chains. TCR Complementarity Determining Regions (CDR) interact directly with peptide-HLA (pHLA). If selection bias has occurred as a result of TCR-pHLA interactions, different individuals may share a similar TCR repertoire to a given pHLA. While deep sequencing synovial tissue has demonstrated oligoclonality, the antigens recognised by these clones are unknown. To obtain more direct evidence that presentation of citrullinated-vimentin shapes the repertoire in SE+ individuals, we profiled TCR repertoire diversity among single vimentin(59-71)cit-64-specific CD4+ T cells.

Methods: Single vimentin(59-71)cit-64-specific CD4+ T cells were sorted from peripheral blood mononuclear cells (PBMC) of 8 HLA-DRB1*0401+ RA patients and 6 HLA-DRB1*0401+ healthy controls (HC), based on staining with fluorescent pHLA tetramers. Sorted cells were simultaneously analysed for expression of CD25 and CD127. At sampling, 2 of the 8 patients had been treated for 18 and 41 months, respectively, 1 had recent-onset untreated RA and 5 had recent-onset RA. PBMC were collected pre- and 1-9 months post-treatment with disease modifying anti-rheumatic drugs. Paired TCR TRAV and TRBV sequences were analysed using multiplex, nested PCR and sequencing.

Results:

A total of 486 vimentin(59-71)cit-64-specific CD4+ T cells with productive TRAV and TRBV sequences were analysed from 8 patients and 6 HC (255 TRAV and 370 TRBV from RA patients; 97 TRAV and 116 TRBV from HCs). Among these T cells, the repertoire encoding TCRα and TCRβ was highly diverse in all patients and HC, and included a large number of unique CDR3 sequences. However, TCR usage in the epitope-specific population differed between RA patients and HC. In RA patients, TRAV26-1 (8%) and TRBV20-1 (13%) predominated while in HC, TRAV13-2 (12%) and TRBV20-1 (12%) were dominant. We did not observe preferential usage in the length of CDR3α or CDR3β. Repeated sequences of individual clonotypes were observed in 3/8 RA patients, but in none of the 6 HC. This oligoclonality was present in pre- and post-treatment samples, and in some cases the same sequences were observed in the same individual across time-points. The repeated sequences were exclusively derived from CD25+CD127+ effector CD4+ T cells.

Conclusion: These data demonstrate a wide range of possible TCRs available for recognition of the vimentin(59-71)cit-64 epitope in PB CD4+ T cells of RA patients and HC. While CD4+ T cells recognising citrullinated self-antigens are present in RA patients and HC carrying HLA-DRB1*0401, repeated clonotypic sequences only among RA patients suggests selective citrullinated self-antigen-driven oligoclonal effector T cell expansion in disease.


Disclosure: S. C. Law, None; H. Nel, None; J. Rossjohn, None; H. H. Reid, None; N. L. La Gruta, None; R. Thomas, None.

To cite this abstract in AMA style:

Law SC, Nel H, Rossjohn J, Reid HH, La Gruta NL, Thomas R. Profiling at the Single-Cell Level Reveals Evidence for Antigen-Driven Oligoclonal Expansion of Citrullinated Vimentin-Specific CD4+ T Cells in Peripheral Blood of Rheumatoid Arthritis (RA) Patients [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/profiling-at-the-single-cell-level-reveals-evidence-for-antigen-driven-oligoclonal-expansion-of-citrullinated-vimentin-specific-cd4-t-cells-in-peripheral-blood-of-rheumatoid-arthritis-ra-patients/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/profiling-at-the-single-cell-level-reveals-evidence-for-antigen-driven-oligoclonal-expansion-of-citrullinated-vimentin-specific-cd4-t-cells-in-peripheral-blood-of-rheumatoid-arthritis-ra-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology